Bank Julius Baer & Co. Ltd Zurich Grows Holdings in Moderna, Inc. (NASDAQ:MRNA)

Bank Julius Baer & Co. Ltd Zurich grew its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 52.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 202,524 shares of the company's stock after purchasing an additional 69,441 shares during the period. Bank Julius Baer & Co. Ltd Zurich owned about 0.05% of Moderna worth $20,141,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of MRNA. First Pacific Financial purchased a new position in shares of Moderna during the third quarter valued at $27,000. Arlington Trust Co LLC increased its stake in shares of Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company's stock valued at $29,000 after buying an additional 290 shares during the period. GPS Wealth Strategies Group LLC increased its stake in shares of Moderna by 54.1% during the third quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company's stock valued at $53,000 after buying an additional 180 shares during the period. Archer Investment Corp increased its stake in shares of Moderna by 71.2% during the third quarter. Archer Investment Corp now owns 534 shares of the company's stock valued at $55,000 after buying an additional 222 shares during the period. Finally, Parkside Financial Bank & Trust boosted its position in Moderna by 44.9% during the third quarter. Parkside Financial Bank & Trust now owns 565 shares of the company's stock valued at $58,000 after purchasing an additional 175 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Stock Performance

MRNA stock traded up $1.79 during midday trading on Friday, hitting $107.97. 2,245,667 shares of the stock traded hands, compared to its average volume of 4,077,747. The firm has a market cap of $41.34 billion, a P/E ratio of -8.70 and a beta of 1.62. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The stock's fifty day simple moving average is $102.15 and its 200-day simple moving average is $93.73. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $142.79.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, beating the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm's revenue was down 44.9% on a year-over-year basis. During the same quarter last year, the business earned $3.61 earnings per share. On average, analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current year.

Insider Activity

In other news, CFO James M. Mock sold 647 shares of Moderna stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares in the company, valued at $406,651. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CFO James M. Mock sold 647 shares of the firm's stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the transaction, the chief financial officer now directly owns 4,300 shares of the company's stock, valued at $406,651. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO James M. Mock sold 705 shares of the firm's stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the completion of the transaction, the chief financial officer now directly owns 5,048 shares in the company, valued at $514,542.64. The disclosure for this sale can be found here. Insiders have sold a total of 109,954 shares of company stock worth $11,533,976 over the last 90 days. 15.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Oppenheimer raised Moderna from a "market perform" rating to an "outperform" rating and set a $142.00 price objective on the stock in a research report on Tuesday, January 2nd. Royal Bank of Canada reaffirmed an "outperform" rating and set a $125.00 price objective on shares of Moderna in a research report on Thursday, March 28th. Needham & Company LLC restated a "hold" rating on shares of Moderna in a report on Thursday, April 11th. William Blair reissued a "market perform" rating on shares of Moderna in a research report on Monday, April 1st. Finally, HSBC reaffirmed a "reduce" rating and issued a $86.00 price target (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $126.49.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.